89 results about "Dosing schedules" patented technology

Method for digitally determining the daily insulin regimen for a diabetic patient. The invention divides the patient's day into adjustable time intervals containing basal insulin dosage rates and Carbohydrate-to-Insulin Ratio(s) (for determining meal insulin doses). The invention identifies the Corrective Insulin doses over a time interval as an “error” in the Prescription Insulin (Basal Insulin+Meal Insulin). Methods involve first estimating the change to one of these two components of Prescription Insulin, and then determining the change to the other by subtracting from the error. One method estimates Change in Meal Insulin distributed among intervals proportional to old Meal Insulin. Another method lumps After-Meal Corrective Insulin together with Meal Insulin. Another method splits the interval at the After-Meal Corrective Dose and determines Basal from Time-Boundary Corrective Dose. Data may be obtained from the previous day, and a small fraction of error applied, leading to asymptotic reduction of error. Data may be obtained from recent history, and a larger fraction of error applied by doctor or automatic method.

A system and method for creating a series of individualized custom doses for a consumer. The individualized doses being delivered in a package or packages, such that each individualized custom dose, comprising a plurality of medications and/or supplements, is individually separable from the remaining doses within the series. By way of example, and not of limitation, a system is described having a web based front-end interface within which the user may establish a dosing schedule, select supplements and/or medications (MS) from an MS database, elect which MS are to be included in each dose, and communicate the order to be processed by a packetizing system. The packetizing system utilizes a conveyance device which interconnects a series of pill dispensing bins. The conveyance device has compartments for collecting a series of doses which are then packetized and shipped for use by the consumer.

A method of dosing a reagent into an exhaust gas stream of an internal combustion engine having an SCR catalyst, the method comprising injecting reagent from a reagent tank into the exhaust gas stream at a position upstream of the SCR catalyst using a reagent injector in accordance with a first dosing schedule in order to remediate a predetermined proportion of NOx in the exhaust gas stream, the first dosing schedule being associated with a first range of engine operating conditions; and injecting reagent from the reagent tank into the exhaust gas stream at a position upstream of the SCR catalyst using a reagent injector in accordance with a second dosing schedule in order to enable heat transfer between the reagent injector and said injected reagent, the second dosing schedule being associated with a second range of engine operating conditions.

Dosing in accordance with said first or said second dosing schedule is carried out in dependence on whether engine operating conditions lie within said first or said second range of engine operating conditions, and the proportion of NOx in the exhaust gas stream which is remediated by dosing using said second dosing schedule is less than said predetermined portion. A reagent dosing system is also provided for dosing a reagent into the exhaust gas stream of an internal combustion engine, comprising a reagent tank for storing a supply of reagent, an injector module comprising an atomising dispenser and a positive-displacement metering pump which draws reagent from the reagent tank and delivers it to the dispenser a supply line coupling the reagent tank to the injector module, and a dosing control unit operable to control the injector module to inject reagent into the exhaust gas stream. A priming pump is provided to urge reagent along the supply line toward the injector module under selected conditions.

This invention relates to a method of treatment and dosing regimen for treating mammalian tumors by the discontinuous administration of a farnesyl transferase inhibitor over an abbreviated one to five day dosing schedule.

The invention is directed to methods for the a method for treating overexpression of the erbB2 in a mammal in need of treatment by administering to the mammal a therapeutically effective amount of a first inhibitor of an erbB2 receptor and then, after an interval of less than 24 hours, administering to the mammal from one to six therapeutically effective amounts of the same or different inhibitor of the erbB2 receptor. The invention is also directed to a slow daily infusion of the erbB2 inhibitor. The overexpression of the erbB2 receptor can result in abnormal cell growth and lead to cancer. By the methods of the invention, the efficacy and safety of the inhibitors is increased. The invention is also directed to kits for facilitating the dose administration method of the invention.

An automated medication dispenser which includes a storage container having a plurality of storage columns configured to store a plurality of pills, an input slot, an output slot, automated means for delivering pills from the input slot to the storage columns, and automated means for delivering pills from the storage columns to the output slot on a time-based or meal-based dosing schedule.

Improved dosing schedules for ecteinascidin 743 are given for treatment of cancer.

The present invention provides for methods and pharmaceutical compositions for treating disorders using treatment regimens involving multiple agents. In one aspect, a method of treatment is provided resulting in reduced toxicity and/or synergistic effect by administration according to a described dosing schedule.

This disclosure relates to drug delivery methods and related products. In some aspects, a method includes selecting a drug vial combination by comparing a prescribed drug dosage to a dosing schedule, and delivering substantially all of the first drug from each of the selected drug vials to a patient by operating a pump of a drug delivery device to which the drug vials are connected.

A medication dispensing device is provided. The device has a storage compartment which stores the user's medication, a programming means whereby a caregiver can input dosage schedules and dosage instructions, and a display which shows the users dosage information. The device can be equipped with communication devices which will allow caregivers to monitor dosing schedules and dosage levels.

A method is provided for reducing the treatment burden for patients who have an intraocular neovascular disorder, the method comprising administering a therapeutically effective amount of VEGF antagonist on a dosing schedule that includes treatment intervals of 8 and/or 12 weeks.

A method and system facilitate enrollment of a customer in a medication compliance packaging program. The medication compliance packaging program facilitates proper dosing of each included medication dispensing each medication in a customized package and thereby serving as a personalized, prepackaged pill organizer. The compliance package groups all of the customer's daily pills, separated by the day and time of day that the customer takes each dose. The disclosed method and system provide a convenient means for a customer to enroll in the program, select prescription medications to include in the medication compliance packaging, and set up a dose schedule for each medication.

The present invention discloses a method for treating or preventing a bone disorder in a mammal in need thereof comprising orally administering to said mammal a pharmaceutically effective amount of a pharmaceutical composition of at least one bisphosphonate, or a pharmaceutically acceptable salt or esters thereof, and at least one aminoalky methacrylate copolymer, according to a dosing schedule having a dosing interval selected from once-weekly dosing, twice-monthly dosing, once-monthly, once-quarterly and once-annually dosing. The present invention further discloses a method for treating or preventing a bone disorder in a mammal in need thereof comprising continuously orally administering a unit dosage per-day to said mammal in a short time for a long time therapy.

Peripherally-acting opioid antagonists can be orally administered to treat the side effects of opioid administration in convenient dosing schedules.

The present invention is directed to a novel orally dispersible multi-micronutrient dietary supplement in a tablet dosage form. Use of lipid encapsulated substrates, flavorings, sweeteners and bitter masking agents provides for a dosage that suppresses unpleasant tastes or aftertastes and imparts a pleasant mouth feel when the tablet disperses after being sucked or chewed for several minutes. The combination of lipid encapsulated substrates, oral disintegration and multiple daily dosing schedule provides for improved bioavailability of several crucial micronutrients.

An arthropod trap with an aerosol dispenser that is remotely controllable to dispense spray doses of an active ingredient such as a pheromone or other semiochemical. Images are captured of trapping media within the trap and are wirelessly communicated to a remote server or application. The dispenser is preferably upside down with the nozzle near the lower extremity of the inverted dispenser. An actuation mechanism controls the spray dose according to a schedule or according to individual sprays commands, each of which may be received wirelessly by the trap. Images of the trapping media may be used as feedback for verifying or modifying the metered dosing schedule.

The invention provides a method of treatment of colorectal cancer by administration of the anti-cancer platinum drug picoplatin in conjunction with 5-FU and leucovorin in a variety of treatment regimens. Dosages, dosing schedules, and ancillary treatments are described.

Compositions comprising a cancer drug, a continuous oral dosing schedule with a drug which binds to the colchicine site of tubulin β-subunits, and methods of treating cancer in a pediatric patient using continuous dosing schedules are disclosed.

A programmable medication dispenser is provided to securely dispense medication to a patient and mitigate the risk of diversion of the medication to an unauthorized user. The programmable medication dispenser may include a processor, a memory, a housing, a biometric verification module, an inner receptacle having a plurality of compartments for storing the medication, and a gate for dispensing the medication from one of the compartments. A patient may access the medication stored within the medication dispenser according to a prescribed dosing schedule based on instructions executed by the processor after verifying his or her identify via the biometric verification module. A system is also provided for securely dispensing, monitoring, controlling medication for a patient using the programmable medication dispenser and for mitigating the risk of diversion of the medication to an unauthorized user. The system could be implemented in a cloud-based environment wherein centralized, cloud-based monitoring and control of a network of medication dispensing systems is provided, and the system could function as a centralized portal for allowing healthcare providers to access patient healthcare data, as well as for allowing insurers and other entities to access such data, as needed.

The invention provides new uses for specific binders to the Al domain of the von Willebrand Factor (vWF), in particular the use in patients with stable angina undergoing elective percutaneous coronary intervention. Furthermore, dosing schedules and use of suitable assays such as RIPA and RICO in the particular disease settings are provided.

A method of treating otosclerosis in a human in need thereof by administering a bisphosphonate in a defined dosing schedule. The invention demonstrates an effective response and sustained benefit in the treatment of otosclerosis. Particularly, the method involves administration of a bisphosphonate in a stepped-up dosage amount, e.g., in a dose that is at least one and a half times the recommended dose for osteoporosis. It also includes administration of a time-dependent dose of more than one bisphosphonate, specifically, alternating administration of a first bisphosphonate with a second bisphosphonate. The inventive method further includes intravenous administration of a bisphosphonate, and optionally oral administration of a bisphosponate. The present invention further contemplates a kit for facilitating the alternating bisphosphonate dosing schedule

The present invention provides a thin mucoadhesive sublingual film composition which provides improved allergen delivery and efficacy at a smaller dose while prolonging the contact time between the allergen and oral antigen presenting cells (APCs), and therefore minimizing the risk of systemic side effects. The thin film compositions of the present invention are also easier to standardize, and removes any need for measuring allergen doses at the physician's office, and which allows for a simplified dosing schedule. Methods of making the thin film compositions and methods for their use are also disclosed.

Compositions comprising one or more cancer drugs, continuous oral dosing schedule with drugs which bind to the colchicine site of tubulin β-subunits, and methods of treating diseases using continuous dosing schedules are disclosed.